Innate Pharma S.A. (IPHA) is a Biotechnology company in the Healthcare sector, currently trading at $1.63. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is IPHA = $5 (+206.7% upside).
Valuation: IPHA trades at a trailing Price-to-Earnings (P/E) of -2.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Financials: revenue is $3M, -54.5%/yr average growth. Net income is $47M (loss), growing at -154%/yr. Net profit margin is -1694.9% (negative). Gross margin is 100% (+103.5 pp trend).
Balance sheet: total debt is $23M with negative equity of -$22M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.27 (adequate). Debt-to-assets is 36%. Total assets: $63M.
Analyst outlook: 4 / 6 analysts rate IPHA as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 25/100 (Fail), Moat 50/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
